NCT05101096: Study of Sacituzumab Govitecan-hziy (SG) in Japanese Participants With Advanced Solid Tumors or Triple-negative Breast Cancer

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 20 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Only triple negative breast cancer (TNBC) patients will be eligible for phase 2 expansion phase of the trial
Exclusions: Patients who have previously received antibody drug conjugate containing topoisomerase I inhibitors

Comments are closed.

Up ↑